AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 800383 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphenadrine hydrochloride (Disipal)
Number of subjects: 0
Study 800383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofenacin hydrochloride (Elamol)
Number of subjects: 0
Study 800383 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate therapy
Number of subjects: 0
Study 31302517 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-asymmetry neurofeedback (ALAY)
Number of subjects: 87
Study 31302517 — intervention group
Group type: EXPERIMENTAL
Intervention: High-beta down-training neurofeedback (Beta)
Number of subjects: 87
Study 31302517 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 27054501 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite stress management training (SMT) intervention
Number of subjects: 153
Study 27054501 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 153
Study 25721186 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaver-NETT (Nonverbal communication, Emotion recognition, and Theory of mind Training)
Number of subjects: 69
Study 25721186 — intervention group
Group type: COMPARATOR
Intervention: Facilitated play group (active control)
Number of subjects: 69
Study 23599941 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression (defined by a CES-D score of 4 or more)
Number of subjects: 2160
Study 23599941 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression
Number of subjects: 2160
Study 23599941 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI with coexisting depression at baseline
Number of subjects: 2160
Study 21697501 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g testosterone gel daily for 6 months
Number of subjects: 209
Study 21697501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 18269306 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic disease management (DM)
Number of subjects: 1069
Study 16545747 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 960
Study 16545747 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 960
Study 16545747 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 960
Study 12631047 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3.5 mg kg(‐1)
Number of subjects: 90
Study 12631047 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg kg(‐1)
Number of subjects: 90
Study 12631047 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg kg(‐1)
Number of subjects: 90
Study 11090727 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil induction (0.5 microg/kg/min) and maintenance (0.25 microg/kg/min)
Number of subjects: 75
Study 11090727 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (maximum of 250 microg)
Number of subjects: 75
Study 11090727 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 75
Study 11090727 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and Fentanyl
Number of subjects: 75
Study 9180665 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 2.5 mg qd (increased to 5 mg qd after 3 weeks and to 10 mg qd after 6 weeks if SDBP > 90 mm Hg)
Number of subjects: 243
Study 9180665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 1609548 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-PRP/D vaccine (109 children)
Number of subjects: 175
Study 1609548 — intervention group
Group type: COMPARATOR
Intervention: DTP vaccine (66 children)
Number of subjects: 175
Study 4027146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (5-20 mg three times daily)
Number of subjects: 20
Study 4027146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4027146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine and Atenolol combination
Number of subjects: 20
Study 31972657 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam continuous IV infusion at 5 mg/min for 5 min, 3 mg/min for 15 min, and 1 mg/min for 15 min
Number of subjects: 20
Study 31972657 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam continuous IV infusion
Number of subjects: 20
Study 29803816 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person group lifestyle intervention
Number of subjects: 211
Study 29803816 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone group lifestyle intervention
Number of subjects: 211
Study 29803816 — intervention group
Group type: COMPARATOR
Intervention: Individual medical nutrition therapy (MNT)
Number of subjects: 211
Study 27684634 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care program
Number of subjects: 119
Study 27684634 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (Control)
Number of subjects: 119
Study 25087939 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic polypropylene mesh placement
Number of subjects: 0
Study 25087939 — intervention group
Group type: COMPARATOR
Intervention: Standard abdominal wall closure (nonmesh)
Number of subjects: 0
Study 22094430 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated interactive telephone system for data collection (75.7% of data collected)
Number of subjects: 0
Study 22094430 — intervention group
Group type: COMPARATOR
Intervention: Alternative methods for data provision (personal phone call or post)
Number of subjects: 0
Study 20418403 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 1909
Study 20418403 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs about the influenza vaccine
Number of subjects: 1909
Study 18041735 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg daily for 10 days with amprenavir 600 mg twice daily added at day 11
Number of subjects: 55
Study 18041735 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz with dual PIs (nelfinavir, indinavir, ritonavir, saquinavir)
Number of subjects: 55
Study 18041735 — intervention group
Group type: COMPARATOR
Intervention: nelfinavir
Number of subjects: 55
Study 18041735 — intervention group
Group type: COMPARATOR
Intervention: indinavir
Number of subjects: 55
Study 18041735 — intervention group
Group type: COMPARATOR
Intervention: ritonavir
Number of subjects: 55
Study 18041735 — intervention group
Group type: COMPARATOR
Intervention: saquinavir
Number of subjects: 55
Study 16025964 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuihuang decoction rectoclysis (RTD)
Number of subjects: 175
Study 16025964 — intervention group
Group type: COMPARATOR
Intervention: Control group (western medicine plus double faced blue treatment)
Number of subjects: 175
Study 12842378 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 0
Study 12842378 — intervention group
Group type: COMPARATOR
Intervention: Various combinations of surgery and radiotherapy
Number of subjects: 0
Study 12842378 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life considerations
Number of subjects: 0
Study 10799372 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BCS (approximately 45 g)
Number of subjects: 38
Study 10799372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose BCS (approximately 25 g)
Number of subjects: 38
Study 10799372 — intervention group
Group type: COMPARATOR
Intervention: Starch-free placebo
Number of subjects: 38
Study 8625493 — intervention group
Group type: COMPARATOR
Intervention: Diet B (6 day standard diet avoiding well‐known dietary inducers and inhibitors of CYP)
Number of subjects: 16
Study 8625493 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C (12 day dietary supplement to the standard diet of 500 g/day broccoli)
Number of subjects: 16
Study 8625493 — intervention group
Group type: COMPARATOR
Intervention: Diet A (customary home diet)
Number of subjects: 16
Study 1453032 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1000 mg)
Number of subjects: 270
Study 1453032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 3894277 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2)
Number of subjects: 150
Study 3894277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (14 mg/m2)
Number of subjects: 150
Study 3894277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisantrene (260 mg/m2)
Number of subjects: 150
Study 3894277 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (cross-over response)
Number of subjects: 150
Study 3894277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (cross-over response)
Number of subjects: 150
Study 3894277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisantrene (cross-over response)
Number of subjects: 150
Study 3894277 — intervention group
Group type: EXPERIMENTAL
Intervention: All agents
Number of subjects: 150
Study 3894277 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 150
Study 3894277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone and Bisantrene
Number of subjects: 150
Study 31266709 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 0
Study 28181386 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home rehabilitation (physical treatment program once a week and basic nursing care)
Number of subjects: 200
Study 28181386 — intervention group
Group type: COMPARATOR
Intervention: Non-rehabilitation group (basic in-home nursing care)
Number of subjects: 200
Study 26047392 — intervention group
Group type: COMPARATOR
Intervention: Nefopam-based PCA (N group)
Number of subjects: 94
Study 26047392 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-based PCA (F group)
Number of subjects: 94
Study 23501976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 3787
Study 23501976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3787
Study 21790771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with xylazine (0.5 mg/kg bwt, iv)
Number of subjects: 6
Study 21790771 — intervention group
Group type: COMPARATOR
Intervention: No sedation (control)
Number of subjects: 6
Study 19361725 — intervention group
Group type: EXPERIMENTAL
Intervention: Jig exercise
Number of subjects: 10
Study 19361725 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching movements
Number of subjects: 10
Study 19361725 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control period)
Number of subjects: 10
Study 16729229 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 34
Study 16729229 — intervention group
Group type: COMPARATOR
Intervention: Control (diagnostic angiography)
Number of subjects: 34
Study 15569584 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to televised alcohol commercials (measured by viewing television programs containing alcohol commercials)
Number of subjects: 0
Study 11237056 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (12 mg/m2/day for 3 days)
Number of subjects: 293
Study 11237056 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (60 mg/m2/day for 3 days)
Number of subjects: 293
Study 9552042 — intervention group
Group type: COMPARATOR
Intervention: CC arm (Carboplatin and Cisplatin)
Number of subjects: 529
Study 9552042 — intervention group
Group type: EXPERIMENTAL
Intervention: CCI arm (Carboplatin, Cisplatin, and Ifosfamide)
Number of subjects: 529
Study 9552042 — intervention group
Group type: EXPERIMENTAL
Intervention: CCI arm
Number of subjects: 529
Study 9552042 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 529
Study 7801618 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA-1bvar platelets
Number of subjects: 0
Study 3286068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1 g, 3 times daily for 10 days
Number of subjects: 89
Study 3286068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 3286068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 89
Study 29875024 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT) guided by esophageal Doppler monitoring
Number of subjects: 90
Study 29875024 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodynamic management
Number of subjects: 90
Study 28651612 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 790
Study 28651612 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation with Contingency Management (PN + CM)
Number of subjects: 790
Study 28651612 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (PN and PN + CM)
Number of subjects: 790
Study 26102552 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytopharmaceutical with Ageratina pichinchensis extract at 5%
Number of subjects: 56
Study 26102552 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone at 0.1%
Number of subjects: 56
Study 23178173 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge instruction
Number of subjects: 10
Study 23178173 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-binge instruction
Number of subjects: 10
Study 23178173 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 10
Study 21770897 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (0.05 g/kg) administered with a rapid infusion diluted in 250 ml of saline solution
Number of subjects: 40
Study 21770897 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 19716456 — intervention group
Group type: EXPERIMENTAL
Intervention: FluBlok-45 (45 microg rHA/antigen)
Number of subjects: 156
Study 19716456 — intervention group
Group type: COMPARATOR
Intervention: TIV (7.5 microg HA/antigen)
Number of subjects: 156
Study 19716456 — intervention group
Group type: EXPERIMENTAL
Intervention: FluBlok-45
Number of subjects: 156
Study 19716456 — intervention group
Group type: COMPARATOR
Intervention: TIV (15 microg HA/antigen)
Number of subjects: 156
Study 16980000 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TMP/SXT (320/1600 mg, daily in two divided doses)
Number of subjects: 95
Study 16980000 — intervention group
Group type: COMPARATOR
Intervention: Low to moderate doses of TMP/SXT (either 80/400 mg or 160/800 mg, daily)
Number of subjects: 95
Study 15250200 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound salvia pellet (CSP)
Number of subjects: 17
Study 15250200 — intervention group
Group type: COMPARATOR
Intervention: Nitrate ester preparation
Number of subjects: 17
Study 11059223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with V.D3 and etidronate (group B)
Number of subjects: 25
Study 11059223 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with active vitamin D3 (group A)
Number of subjects: 25
Study 9493666 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement detectors (pedometers) in COPD patients
Number of subjects: 75
Study 9493666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal nocturnal mechanical ventilation (NMV) in chronic respiratory failure patients
Number of subjects: 75
Study 9493666 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 75
Study 8418608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg per day administered once daily)
Number of subjects: 201
Study 8418608 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (40 mg/kg per day administered in three divided doses)
Number of subjects: 201
Study 8418608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 201
Study 3614304 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate (500 mg)
Number of subjects: 8
Study 3614304 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium lactate (500 mg)
Number of subjects: 8
Study 3614304 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate (500 mg)
Number of subjects: 8
Study 3614304 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate (500 mg)
Number of subjects: 8
Study 3614304 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (500 mg)
Number of subjects: 8
Study 3614304 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk (500 mg)
Number of subjects: 8
Study 29596724 — intervention group
Group type: EXPERIMENTAL
Intervention: A Woman's Path to Recovery (WPR)
Number of subjects: 66
Study 29596724 — intervention group
Group type: COMPARATOR
Intervention: 12-Step Facilitation (TSF)
Number of subjects: 66
Study 26748220 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-BD (n=34)
Number of subjects: 66
Study 26748220 — intervention group
Group type: COMPARATOR
Intervention: PTBD (n=32)
Number of subjects: 66
Study 24682910 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 9
Study 22995802 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg daily (A)
Number of subjects: 33
Study 22995802 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg daily (V)
Number of subjects: 33
Study 22995802 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg + Valsartan 160 mg daily (A+V)
Number of subjects: 33
Study 22995802 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (combined)
Number of subjects: 33
Study 22995802 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren (A) and Aliskiren + Valsartan (A+V)
Number of subjects: 33
Study 20799599 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased price of direct hospital outpatient visits
Number of subjects: 0
Study 20799599 — intervention group
Group type: COMPARATOR
Intervention: Control district (no intervention)
Number of subjects: 0
Study 19080096 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring during intravenous anesthesia with remifentanil and propofol
Number of subjects: 40
Study 17043181 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular running polyglactin 910 sutures left in place
Number of subjects: 36
Study 17043181 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular running polypropylene sutures left in place
Number of subjects: 36
Study 17043181 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular running polypropylene sutures removed after 14 days
Number of subjects: 36
Study 17043181 — intervention group
Group type: COMPARATOR
Intervention: Simple running polypropylene sutures removed after 14 days (Control)
Number of subjects: 36
Study 12723685 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified parcellation method using successive fuzzy c-means (sFCM) and boundary-detection algorithm
Number of subjects: 0
Study 12723685 — intervention group
Group type: COMPARATOR
Intervention: Conventional FCM
Number of subjects: 0
Study 12723685 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method (sFCM)
Number of subjects: 0
Study 12723685 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 0
Study 10795438 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers group (students receiving education through trained teachers)
Number of subjects: 385
Study 10795438 — intervention group
Group type: COMPARATOR
Intervention: Lecture group (students receiving health education lecture by health staff)
Number of subjects: 385
Study 10795438 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 385
Study 9068739 — intervention group
Group type: EXPERIMENTAL
Intervention: benzoyl peroxide 5%/erythromycin 3% gel
Number of subjects: 72
Study 9068739 — intervention group
Group type: COMPARATOR
Intervention: erythromycin 4%/zinc 1.2% solution
Number of subjects: 72
Study 8147168 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 0
Study 8147168 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (control group)
Number of subjects: 0
Study 3535492 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capsules of potassium metabisulfite
Number of subjects: 203
Study 3535492 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind rechallenge with metabisulfite capsules
Number of subjects: 203
Study 30781998 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-based vision screening
Number of subjects: 1000
Study 30781998 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipating practices (Control)
Number of subjects: 1000
Study 28520883 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic fluids (NaCl 0.9% in glucose 5% supplemented by 40 mmol litre ‐1 of potassium chloride)
Number of subjects: 12
Study 28520883 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic fluids (NaCl 0.32% in glucose 5% containing 26 mmol litre ‐1 of potassium)
Number of subjects: 12
Study 28520883 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic fluids
Number of subjects: 12
Study 28520883 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic fluids
Number of subjects: 12
Study 25565530 — intervention group
Group type: EXPERIMENTAL
Intervention: Five successive repeated breath hold maximal efforts (RBHE) separated by 2-min intervals; performed by the NBH group for 14 days.
Number of subjects: 2
Study 25565530 — intervention group
Group type: COMPARATOR
Intervention: Control group (CBH) with no training; HCVR test performed before and after the intervention.
Number of subjects: 2
Study 23280226 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 20
Study 23280226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose ingestion
Number of subjects: 20
Study 21601319 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Enteral Nutrition (EEN)
Number of subjects: 121
Study 21601319 — intervention group
Group type: COMPARATOR
Intervention: Control management (nil by mouth and IV fluid)
Number of subjects: 121
Study 18674932 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous conditioned serum (ACS)
Number of subjects: 376
Study 18674932 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronan (HA)
Number of subjects: 376
Study 18674932 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 376
Study 16769949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ictal eye closure in patients with PNES
Number of subjects: 208
Study 16769949 — intervention group
Group type: COMPARATOR
Intervention: Ictal eye opening in patients with epileptic seizures (ES)
Number of subjects: 208
Study 15580212 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hypothermia
Number of subjects: 26